Generic drugmaker Mylan Mylan wants to put speculation of a possible merger with Teva Pharmaceuticals to rest. A potential deal, the company said, is “without sound industrial logic” and would have a hard time winning anti-trust clearances.
Mylan’s comments on Friday responded to reports from both Bloomberg and the Wall Street Journal that indicated Teva Pharmaceutical is considering a bid for the company. Speculation of a Teva bid pushed Mylan shares higher by over 4% on Friday, closing trading at a $32 billion market capitalization. ...
16:16 Luxottica, Essilor $24 billion merger creates eyewear giant18
21:52 Netflix nears 94 million subscribers 10 years after streaming launch17
22:33 Allergan to pay $15 million over failing to disclose merger talks19
18:21 Mark Zuckerberg takes the stand in $2 billion lawsuit claiming Oculus theft8